Skip to main navigation Skip to search Skip to main content

Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases

Research output: Contribution to journalReview articlepeer-review

Abstract

The development of safe and affordable antiparasitic agents effective against neglected tropical diseases is a big challenge of the drug discovery. The drugs currently employed have limitations such as poor efficacy, drug resistance or side effects. Thus, the search for new promising drugs is more and more crucial. Metal complexes and, in particular, organometallic compounds may expand the list of the drug candidates due to the peculiar attributes that the presence of the metal core add to the organic fragment (e.g., redox and structural features, ability to interact with DNA or protein targets, etc.). To date, most organometallic compounds tested as anti-neglected tropical diseases are based on similarities or activity of the organic ligands against other diseases or parasites and/or consist in modification of existing drugs combining the features of the metal moiety and the organic ligands. This review focuses on recent studies (2012–2017) on organometallic compounds in treating kinetoplastid-caused diseases such as Human African trypanosomiasis, Chagas disease and leishmaniasis. This field of research, however, still lacks exhaustive studies to identify of parasitic targets and quantitative structure-activity relationships for a rational drug design.

Original languageEnglish
Pages (from-to)459-482
Number of pages24
JournalEuropean Journal of Medicinal Chemistry
Volume155
DOIs
Publication statusPublished - 15 Jul 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Chagas disease
  • Leishmania
  • Metal-based drugs
  • Organometallic compounds
  • Trypanosoma

Fingerprint

Dive into the research topics of 'Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases'. Together they form a unique fingerprint.

Cite this